By Business/Source
Currency:USD
2025/FY
Stock NameRevenueRatio
Developing and commercializing genome editing technology40.52M100.00%
By Country/Region
Currency:USD
2025/FY
Stock NameRevenueRatio
United States40.52M100.00%